Kanda, S., Mizutani, T., Nomura, S., Goto, Y., Kida, G., Taniguchi, H., Tanaka, H., Yokoyama, T., Azuma, K., Iwama, E., Toi, Y., Toyozawa, R., Hayashi, H., Daga, H., Shimizu, J., Ohe, Y., Niho, S., Okamoto, I. (2026). Five-year outcomes of osimertinib-based treatment in a phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin plus pemetrexed as a first-line treatment for advanced non-squamous non–small-cell lung cancer harboring EGFR mutation (JCOG1404/WJOG8214L).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8649